Literature DB >> 15620886

Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study.

Wei Guo1, Jenifer L Johnson, Sumsullah Khan, Ateeq Ahmad, Imran Ahmad.   

Abstract

A liquid chromatography-tandem mass spectrometry assay to quantify total paclitaxel in mouse plasma and tissue homogenates containing paclitaxel, Taxol, or liposome-entrapped paclitaxel-easy to use (LEP-ETU) was developed and validated. Docetaxel was used as the internal standard (IS). Liquid-liquid extraction with tert-butyl methyl ether was used for plasma sample preparation, and a one-step protein precipitation with acetonitrile containing 0.1% acetic acid was developed for tissue homogenates. Paclitaxel and IS are separated on a 50 x 2.1-mm C18 column and quantified using a triple-quadrupole mass spectrometer operating in positive ion electrospray multiple reaction monitoring mode, with a total run time of 3.5 min. The peak area of the m/z 854.4--> 286.2 transition of paclitaxel is measured versus that of the m/z 808.5--> 527.5 transition of IS to generate the standard curve. In plasma, the linear range is 0.2-500 ng/mL and could be extended by dilution to 100,000 ng/mL with acceptable precision and accuracy (< or = 15%). The lower limit of quantification is 0.5 ng/mL in tissue homogenates (10 ng/g tissue), and the standard curve is linear up to 1000 ng/mL, with precision and accuracy < or = 15%. This assay was used to support a pharmacokinetics and tissue distribution study of LEP-ETU in mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15620886     DOI: 10.1016/j.ab.2004.09.046

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  10 in total

1.  Advances of cancer therapy by nanotechnology.

Authors:  Xu Wang; Yiqing Wang; Zhuo Georgia Chen; Dong M Shin
Journal:  Cancer Res Treat       Date:  2009-03-31       Impact factor: 4.679

2.  Structural Characterization of Anticancer Drug Paclitaxel and Its Metabolites Using Ion Mobility Mass Spectrometry and Tandem Mass Spectrometry.

Authors:  Hong Hee Lee; Areum Hong; Yunju Cho; Sunghwan Kim; Won Jong Kim; Hugh I Kim
Journal:  J Am Soc Mass Spectrom       Date:  2016-02       Impact factor: 3.109

3.  Peptidyl alpha-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors.

Authors:  Asli Ovat; Zhao Zhao Li; Christina Y Hampton; Seneshaw A Asress; Facundo M Fernández; Jonathan D Glass; James C Powers
Journal:  J Med Chem       Date:  2010-09-09       Impact factor: 7.446

4.  Highly selective and sensitive assay for paclitaxel accumulation by tumor cells based on selective solid phase extraction and micro-flow liquid chromatography coupled to mass spectrometry.

Authors:  Julio R Gaspar; Jun Qu; Ninfa L Straubinger; Robert M Straubinger
Journal:  Analyst       Date:  2008-10-03       Impact factor: 4.616

5.  Ultra-sensitive quantification of paclitaxel using selective solid-phase extraction in conjunction with reversed-phase capillary liquid chromatography/tandem mass spectrometry.

Authors:  Haoying Yu; Robert M Straubinger; Jin Cao; Hao Wang; Jun Qu
Journal:  J Chromatogr A       Date:  2008-09-19       Impact factor: 4.759

6.  Targeted paclitaxel delivery to tumors using cleavable PEG-conjugated solid lipid nanoparticles.

Authors:  Jie Zheng; Yu Wan; Abdelbary Elhissi; Zhirong Zhang; Xun Sun
Journal:  Pharm Res       Date:  2014-03-05       Impact factor: 4.200

7.  Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial).

Authors:  Luo Hu; Gong Liang; Wang Yuliang; Zhu Bingjing; Zhou Xiangdong; Xu Rufu
Journal:  Trials       Date:  2013-02-15       Impact factor: 2.279

8.  Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology.

Authors:  Sihem Ait-Oudhia; Donald E Mager; Robert M Straubinger
Journal:  Pharmaceutics       Date:  2014-03-18       Impact factor: 6.321

9.  The ameliorative effects of exogenous inoculation of Piriformospora indica on molecular, biochemical and physiological parameters of Artemisia annua L. under arsenic stress condition.

Authors:  Saeed-Ur- Rahman; Muhammad Khalid; Sadaf-Ilyas Kayani; Kexuan Tang
Journal:  Ecotoxicol Environ Saf       Date:  2020-09-01       Impact factor: 6.291

10.  Assembly of bio-nanoparticles for double controlled drug release.

Authors:  Wei Huang; Jianfei Zhang; Harry C Dorn; Chenming Zhang
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.